Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GDLEY
ADC Name
STI-6129
Synonyms
LNDS-1001; STI 6129
   Click to Show/Hide
Organization
Sorrento Therapeutics, Inc.; Zhejiang ACEA Pharmaceutical Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Phase 2
Antibody Name
SC16.3
  Antibody Info 
Antigen Name
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
  Antigen Info 
Payload Name
DUO-5.2
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Site-specific conjugation through a non-polyethylene glycol linker.
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05565807
Phase 1/2
A phase 1b/2a, open-label, dose-escalation and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.

   Click to Show/Hide
Undisclosed  NCT05308225
Phase 1/2
A phase 1b/2a, open-label, dose-escalation study of the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
Undisclosed  NCT04316442
Phase 1/2
A phase 1b/2a, open-label, dose-escalation study of the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory systemic al amyloidosis.
Undisclosed  NCT05692908
Phase 1
An open-label, dose-escalation study of the safety of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory systemic al amyloidosis.
Undisclosed  NCT05584709
Phase 1
A phase 1b, open-label, dose-escalation study of the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with advanced solid tumors.
Undisclosed  NCT05519527
Phase 1
A phase 1 study of safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory t-acute lymphoblastic leukemia/lymphoma (T-ALL) or acute myeloid leukemia (AML).

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with relapsed/refractory (RR) myeloma.
Administration Dosage
Dose range from 0.25 mg/kg to 3.68 mg/kg.
Related Clinical Trial
NCT Number NCT05565807  Clinical Status Phase 1/2
Clinical Description A phase 1b/2a, open-label, dose-escalation and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05308225  Clinical Status Phase 1/2
Clinical Description A phase 1b/2a, open-label, dose-escalation study of the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT04316442  Clinical Status Phase 1/2
Clinical Description A phase 1b/2a, open-label, dose-escalation study of the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory systemic al amyloidosis.
Experiment 4 Reporting the Activity Date of This ADC [4]
Related Clinical Trial
NCT Number NCT05692908  Clinical Status Phase 1
Clinical Description An open-label, dose-escalation study of the safety of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory systemic al amyloidosis.
Experiment 5 Reporting the Activity Date of This ADC [5]
Related Clinical Trial
NCT Number NCT05584709  Clinical Status Phase 1
Clinical Description A phase 1b, open-label, dose-escalation study of the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with advanced solid tumors.
Experiment 6 Reporting the Activity Date of This ADC [6]
Related Clinical Trial
NCT Number NCT05519527  Clinical Status Phase 1
Clinical Description A phase 1 study of safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory t-acute lymphoblastic leukemia/lymphoma (T-ALL) or acute myeloid leukemia (AML).
References
Ref 1 First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer. Cancer Res (2020) 80 (16_Supplement): CT167.
Ref 2 A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma, NCT05308225
Ref 3 A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis, NCT04316442
Ref 4 An Open-Label, Dose-Escalation Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis, NCT05692908
Ref 5 A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Advanced Solid Tumors, NCT05584709
Ref 6 A Phase 1 Study of Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) or Acute Myeloid Leukemia (AML), NCT05519527

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.